Your session is about to expire
← Back to Search
Media Literacy + Text Messaging Support + Financial Incentives for Smoking Cessation
N/A
Recruiting
Led By Tzeyu Michaud, PhD
Research Sponsored by University of Nebraska
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights
Study Summary
This trial tests if a program of media literacy, real-time text messages & incentives can help people quit vaping, with the aim of reducing rates of abstinence.
Who is the study for?
This trial is for young adults aged 19-29 who have been vaping regularly for at least 6 months, want to quit, and have asthma. They must be able to access internet or text messaging services but can't use other nicotine products or already be in a quitting program.Check my eligibility
What is being tested?
The study tests if combining media literacy education with real-time texting support and financial rewards helps people stop vaping better than just one of these methods alone. Participants will either get the combined approach or just one part of it.See study design
What are the potential side effects?
Since this trial involves educational and support interventions rather than medications, traditional side effects are not expected. However, participants may experience stress or frustration related to quitting efforts.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Biochemically verified vaping abstinence
Secondary outcome measures
Biomarkers of toxic exposures
Engagement
Media literacy
+2 moreTrial Design
4Treatment groups
Experimental Treatment
Active Control
Group I: CombinedExperimental Treatment3 Interventions
Participants will receive media literacy e-learning lessons, financial incentive, and an evidence-based text-messaging support program.
Group II: Active controlExperimental Treatment1 Intervention
Participants in this arm will receive an evidence-based text-messaging support.
Group III: Financial incentiveActive Control2 Interventions
Participants will receive financial incentive intervention and an evidence-based text-messaging support.
Group IV: Media literacyActive Control2 Interventions
Participants will receive media literacy e-learning lessons and an evidence-based text-messaging support.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Financial incentive
2016
Completed Phase 3
~61520
Find a Location
Who is running the clinical trial?
University of NebraskaLead Sponsor
542 Previous Clinical Trials
1,144,767 Total Patients Enrolled
National Institute of General Medical Sciences (NIGMS)NIH
272 Previous Clinical Trials
246,940 Total Patients Enrolled
Tzeyu Michaud, PhDPrincipal InvestigatorUniversity of Nebraska
1 Previous Clinical Trials
119 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have expressed a wish to stop using vaping products.I am currently participating in a program to stop vaping.I am between 19 and 29 years old.I want to quit vaping within the next month.You have been vaping regularly for at least 6 months and have vaped on at least 25 out of the last 30 days.
Research Study Groups:
This trial has the following groups:- Group 1: Financial incentive
- Group 2: Combined
- Group 3: Active control
- Group 4: Media literacy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger